Molecular Detection of Advanced Neoplasia in Pancreatic Cysts
Molecular Detection of Advanced Neoplasia in Pancreatic Cysts (IN-CYST)
Mayo Clinic
800 participants
May 11, 2018
INTERVENTIONAL
Conditions
Summary
Researchers are trying to find out whether new tests ("biomarkers") of blood, stool, pancreas cyst fluid, or pancreas juice can be used to diagnose malignant or pre-malignant changes in pancreas cysts.
Eligibility
Inclusion Criteria3
- Patients with pancreatic cystic lesions meeting Fukuoka worrisome or Fukuoka high-risk criteris
- Patients with suspected cystic neoplasm of the pancreas
- Able to provide written informed consent
Exclusion Criteria8
- Pregnant and/or nursing
- Incarceration
- Imaging showing possible pancreatic cancer
- Prior history of pancreatic cancer or pancreatic surgery
- History of receiving systemic chemotherapy or abdominal radiation within the last 5 years
- Previous therapy for a pancreatic cystic lesion
- History of pancreatic necrosis
- Diagnosis of cancer (other than non-melanoma skin cancer) within the last 5 years
Interventions
Surgical resection of pancreatic cyst
Clinically indicated endoscopic ultrasound
Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03855800